Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRIBUTE-CM Trial
2018-004280-32Phase 3Unknown
- Sponsor
- Eidos Therapeutics
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing AG10 (acoramidis) with Placebo (2 arms). Primary endpoint: Primary - 6MWT change at 12 months. Status: unknown.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2018-004280-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004280-32.